Future Weight Loss Drugs: Retatrutide, Orforglipron, CagriSema

GLP-1 medications are the current standard of care for medical weight loss. Semaglutide (r) and tirzepatide (r) have shown strong clinical results and changed the weight loss landscape since 2021. But the pipeline is actively developing. The field is moving toward more potent compounds, oral formulations, and combination approaches. Here’s where the most advanced candidates stand and what they might mean for you.

The Direction the Field Is Moving

The evolution of weight loss medications follows a clear pattern: from single-target to multi-target approaches, and from injection-only to oral options.

Current first-generation GLP-1 medications activate one receptor: the GLP-1 receptor. Tirzepatide, approved in 2023, was the first dual agonist, activating both GLP-1 and GIP receptors. That’s why tirzepatide produces greater weight loss than semaglutide alone: more hormonal pathways targeted, more metabolic levers pulled.

The next wave is triple agonists. These activate GLP-1, GIP, and glucagon receptors all in a single molecule. Glucagon activation is the new mechanism. Unlike GLP-1, which suppresses appetite, glucagon directly increases energy expenditure. It tells your liver to burn more fuel. This is why researchers expect triple agonists to produce weight loss beyond what tirzepatide achieves.

Alongside potency gains, the field is solving a major barrier: injections. Oral GLP-1 medications that don’t require injections could dramatically expand who can access treatment and who will stay on it. Some patients avoid injectable medications entirely. Others find injections inconvenient. An effective oral option removes that barrier.

The third major trend is combination approaches. Instead of one molecule doing everything, some compounds pair a GLP-1 with an amylin analog or glucagon agonist. These work through different appetite and metabolic pathways, potentially targeting additional mechanisms.

Retatrutide: The Triple Agonist Leading the Pipeline

Retatrutide (LY3437943) is the most advanced and widely discussed upcoming weight loss medication.

Retatrutide is a triple receptor agonist. It activates GLP-1, GIP, and glucagon receptors in one injection.

The Phase 2 trial data from 2023 was striking. After 48 weeks of treatment, the average weight loss was approximately 24.2%.^[1] That’s the highest efficacy reported in a Phase 2 weight loss trial. For context, semaglutide produces 15-21% weight loss in clinical trials.^[2] Tirzepatide produces 20-21% weight loss.^[3] Retatrutide at 24.2% represents a measurable step forward.

The mechanism explains the magnitude. Tirzepatide’s GIP activation amplifies appetite suppression. Retatrutide adds glucagon on top of that. Glucagon increases metabolic rate by making the liver more efficient at burning energy. This dual mechanism, appetite reduction plus energy expenditure increase, is why retatrutide exceeded expectations in early trials.

As of early 2026, retatrutide is in Phase 3 trials. These are larger, longer trials conducted across multiple centers. If Phase 3 results support FDA submission, approval could come in 2026 or 2027. Timeline estimates depend on trial pace and regulatory timeline.

The important caveats: Phase 3 is larger and longer than Phase 2. Results sometimes differ. Not every Phase 2 success translates to Phase 3 approval. Regulatory approval timelines shift. Adverse event monitoring is more stringent in Phase 3. But if Phase 3 confirms Phase 2 efficacy, retatrutide could represent another significant step forward in weight loss pharmacology.

Orforglipron: Oral GLP-1 Without the Fasting Requirement

Orforglipron (LY3502970) is an oral small-molecule GLP-1 receptor agonist, not a peptide.

This distinction matters practically. Branded oral semaglutide tablets are an oral GLP-1, but they require a 30-minute fasting window before dosing.^[4] Many patients find this restriction cumbersome. Orforglipron can be taken without fasting. It’s a simple daily pill with no pre-dose preparation.

Phase 2 data showed approximately 14.7% average weight loss at 36 weeks.^[5] That’s lower than tirzepatide, but orforglipron is a single-agonist (GLP-1 only), so this aligns with expected efficacy for that class.

The real advantage is access and adherence. Peptide-based medications like semaglutide require cold storage and inject training. Oral small molecules are simpler. They could also be manufactured at lower cost than peptide drugs, potentially lowering prices over time.

As of 2025-2026, orforglipron is in Phase 3 trials. The same caveats apply: Phase 3 outcomes sometimes diverge from Phase 2. But if approved, an oral GLP-1 without fasting requirements could expand the population willing to try medication-assisted weight loss.

CagriSema: GLP-1 Plus Amylin Combination

CagriSema is a combination of two hormones: semaglutide (a GLP-1 receptor agonist) and cagrilintide (an amylin analog).

Amylin is a pancreatic hormone that works alongside insulin. It suppresses appetite through different neural pathways than GLP-1. The logic of combining them is straightforward: target satiety through multiple mechanisms.

Phase 2 data showed approximately 15.6% average weight loss at 32 weeks. Phase 3 data (REDEFINE 1) reported in late 2024 showed approximately 22.7% mean body weight reduction at 68 weeks in the studied population.^[6]

Those numbers place CagriSema in a middle range: better than semaglutide alone, comparable to or slightly better than current tirzepatide results. The combination approach addresses a different question than retatrutide: instead of more receptor targets in one molecule, CagriSema uses two well-studied hormones together.

The manufacturer has indicated that regulatory submission is anticipated, suggesting Phase 3 results were sufficient to move toward FDA review.

The trade-off of a combination approach is complexity. Two drugs mean two injection sites or combined injection. Cost might be higher than a single-molecule agonist. But the data shows the combination works, and some patients may tolerate or prefer it.

Other Compounds Worth Noting

A few other medications in development deserve mention, though they’re earlier in the pipeline.

Amycretin is a single molecule that combines GLP-1 and amylin receptor agonism in one peptide. It’s more advanced than a combination approach, but it’s much earlier in trials (Phase 1/2 as of 2024). Preliminary data showed approximately 13.1% weight loss at 12 weeks, which is notably rapid for such a short trial window.^[7] Very early stage, but the mechanism is intriguing.

Mazdutide (IBI362) is a GLP-1/glucagon dual agonist (not a triple agonist like retatrutide). It’s in Phase 3 trials in China and Phase 2 in US populations. It sits between current tirzepatide and the triple agonists in terms of mechanism.

What This Means: Pipeline Status, Timelines, and Clinical Significance

The field is advancing, but advancement is incremental, not significant.

Retatrutide represents the most significant step forward in mechanism. If Phase 3 confirms Phase 2 data, approval in 2026 or 2027 is plausible. That would make it the first broadly available triple agonist.

Orforglipron’s advantage is access and convenience, not superior efficacy. A non-peptide, non-fasting oral GLP-1 removes injection and preparation barriers. If approved, it would expand the population that can realistically use GLP-1 treatment.

CagriSema represents a combination approach that works, though it’s a bit more complex than single-molecule agonists.

All of these compounds are investigational. They are not FDA-approved. They are not available outside of clinical trials (except where enrolled patients can access them under expanded access provisions, which vary by drug and region). Phase 3 trials can fail. Approval timelines shift. Individual results vary.

What Current Patients Should Know About Waiting vs. Starting

This is the most practical question: if these drugs are coming, should you wait?

The answer depends on your specific situation, and your provider is the right person to discuss it with. But here are the facts.

Current treatments work. Semaglutide and tirzepatide have produced 15-21% average weight loss in rigorous clinical trials.^[8] That’s clinically meaningful. It’s enough to improve metabolic health, reduce cardiovascular risk, and often resolve or improve diabetes.

Waiting for a future drug means continuing to carry weight while regulatory processes unfold. The complications of obesity continue to accumulate: increased visceral fat, metabolic decline, joint stress, cardiovascular strain. These don’t pause while you wait for approval. The real costs of delay are ongoing.

Future drugs may offer improvement. Retatrutide might produce 24%+ weight loss for many patients. That’s a meaningful gain over tirzepatide. But it’s not guaranteed for every individual. Some people respond extremely well to semaglutide and don’t respond to higher-potency drugs. Some people hit a plateau regardless of medication potency.

There’s no guarantee retatrutide will be approved when expected. Timelines slip. If Phase 3 encounters safety signals, approval could be delayed or denied. Waiting for a drug that doesn’t arrive is a real risk.

Starting now means you can measure your actual response. You learn whether this medication class works for you. You stop the weight gain and start the weight loss now, not years from now. If a new drug does approve and offers benefit, you and your provider can discuss switching at that time.

Your provider will help you think through this decision. The conversation should include your current health status, your goals, your response to past treatments, and the tradeoff between starting today versus waiting for something that may offer incremental improvement later.

The Bottom Line

The pipeline is real. Retatrutide looks promising. Oral GLP-1s without fasting restrictions are coming. Combination and amylin-based approaches are advancing.

These compounds represent meaningful progress in weight loss pharmacology. If they approve as expected, they will offer options beyond current medications.

But progress in drug development is measured in years, not months. The complications of obesity are happening now. Current medications are effective now.

Your provider can help you decide whether waiting for a future drug makes sense for your health, your timeline, and your goals. That’s a personalized decision that depends on factors no one-page guide can fully capture.

Citations

[1] “Retatrutide Phase 2 Trial Data: LY3437943 for Chronic Weight Management.” Clinical Trial Summary, 2023. https://www.clinicaltrials.gov/ct2/show/NCT05427357

[2] Wilding JPH et al. “Once-weekly semaglutide in adults with overweight or obesity.” New England Journal of Medicine 2021;385(22):2047-2058. https://pubmed.ncbi.nlm.nih.gov/33567185/

[3] Jastreboff AM et al. “Tirzepatide once weekly for the treatment of obesity.” New England Journal of Medicine 2022;387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/

[4] FDA. “Prescribing Information for oral semaglutide for type 2 diabetes.” U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213051s012lbl.pdf

[5] “Orforglipron Phase 2 Clinical Trial Results.” https://www.clinicaltrials.gov/ct2/show/NCT04615507

[6] “CagriSema REDEFINE 1 Phase 3 Trial Results.” Clinical Trial Data, 2024. https://www.clinicaltrials.gov/ct2/show/NCT05240339

[7] “Amycretin Phase 1/2 Preliminary Data.” Clinical Trial Summary, 2024. https://www.clinicaltrials.gov/ct2/show/NCT04368065

[8] Wilding JPH et al. “Once-weekly semaglutide in adults with overweight or obesity.” New England Journal of Medicine 2021;385(22):2047-2058. https://pubmed.ncbi.nlm.nih.gov/33567185/ AND Jastreboff AM et al. “Tirzepatide once weekly for the treatment of obesity.” New England Journal of Medicine 2022;387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/